Citi cuts target to BRL 10 for Hapvida stock

Published on 10/16/2026 at 02:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi expects a 5.9 percent adjusted margin in the third quarter of 2026. Hapvida stock may lose 91,000 beneficiaries before November 11, 2026.

Pressure and upcoming results

Citi lowered Hapvida's target to BRL 10 on October 14, 2026.
BTG Pactual cited BRL 504 million adjusted EBITDA for the second quarter of 2026.
Hapvida's third-quarter results are scheduled for November 11, 2026.

Hapvida, BRHAPVACNOR4, Illustration mit AI erstellt.

Hapvida (ISIN BRHAPVACNOR4) faces a lower BRL 10 price target from Citi ahead of its third-quarter results, according to Money Times on October 14, 2026. The bank also cut its 2026 and 2027 profit estimates by 5 percent and 12 percent.

Citi target cut reaches BRL 10

The revised target keeps the emphasis on operational execution rather than the recent share-price recovery. Citi projects a net loss of 91,000 beneficiaries in the third quarter of 2026 and revenue growth of 2.6 percent year over year, according to Money Times.

Three dated turning points

On August 13, 2026, Hapvida reported second-quarter revenue of BRL 8.0 billion and adjusted EBITDA of BRL 504 million, down 44 percent from the prior-year quarter, according to BTG Pactual. On October 2, 2026, a report described a potential BRL 1.5 billion sale-leaseback involving hospital properties, according to El-Fondo. On October 14, 2026, Citi reduced its target to BRL 10, the latest of the three developments.

What will test the recovery?

Citi expects the adjusted margin to fall to 5.9 percent in the third quarter of 2026 as medical utilization and restructuring costs weigh on profitability. The bank also estimates recurring free cash flow consumption of BRL 100 million and a 0.8 percentage-point increase in the medical-loss ratio from the prior quarter, according to Money Times. The figures make beneficiary retention, margins and cash generation the central operating tests.

Upcoming reporting dates

Hapvida's third-quarter results are scheduled for November 11, 2026, followed by a results webcast on November 12, 2026, according to TraderNews. The reporting date will put the 5.9 percent margin estimate and the 91,000-beneficiary forecast against the company's actual performance.

B3 quote and investor view

Hapvida was last quoted at BRL 8.52 on B3 on October 15, 2026 at 5:05 p.m. BRT. The company operates in Brazilian healthcare, with medical and dental plans, hospitals, clinics and diagnostic centers.